Clinical trial
Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft…
NCT00032279 · Fred Hutchinson Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00032279 |
|---|---|
| Title | Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease |
| Official title | A Phase II, Multicenter Clinical Trial Evaluating the Use of Humanized Monoclonal Anti-CD3 Antibody Visilizumab(Nuvion) as Second-line Therapy for Glucocorticoid-Refractory, Acute Graft-Versus-Host Disease |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | Facet Biotech Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft-vs-Host Disease |
| Intervention type | Drug |
| Interventions | Visilizumab |
| Enrollment | 80 |
| Start date | Mar 1, 2002 |
| First posted | Mar 18, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: